Satsuma Pharmaceuticals, Inc.
-
Ticker
STSA
-
Industry
Biotechnology More
-
Sector
Healthcare More
- 11-50 Employees
- Based in South San Francisco, California
Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic product for the acute treatment of migraine, STS101. STS101 is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate (DHE), which can be quickly and easily self-administered with a proprietary pre-filled, single-use, nasal delivery device. In developing
…More STS101, Satsuma has applied proprietary nasal drug delivery, dry-powder formulation, and engineered drug particle technologies to create a compact, simple-to-use, non-injectable DHE product that can be rapidly self-administered in a matter of seconds.
Satsuma Pharmaceuticals, Inc.
Most Recent Annual Report
MOST RECENT
2021 Annual Report and Form 10K
Older/Archived Annual Reports